Search research articles
Contact Us
Filters
Showing results (81-90 of 244) with videos related to
Page
of 25
Sort By:
The Journal of Antimicrobial Chemotherapy
|
June 8, 2019
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL
Nicola Gianotti, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
AIDS (London, England)
|
April 13, 2004
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy
Michela Violin, Alessandro Cozzi-Lepri, Rossella Velleca, et al.
AIDS (London, England)
|
April 7, 2007
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
Alessandro Cozzi-Lepri, Andrew N Phillips, Lidia Ruiz, et al.
Antiviral Therapy
|
April 14, 2010
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy
Antonella Castagna, Laura Galli, Carlo Torti, et al.
The Journal of Infectious Diseases
|
July 17, 2009
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings
Alessandro Cozzi-Lepri, Andrew N Phillips, Javier Martinez-Picado, et al.
The Journal of Antimicrobial Chemotherapy
|
September 11, 2019
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort
Lucia Taramasso, Patrizia Lorenzini, Antonio Di Biagio, et al.
HIV Medicine
|
April 28, 2025
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort
Andrea De Vito, Alessandro Tavelli, Alessandro Cozzi-Lepri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 13, 2005
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study
Rita Murri, Alessandro Cozzi Lepri, Paola Cicconi, et al.
HIV Clinical Trials
|
March 2, 2018
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort<sup/>
Antonella d'Arminio Monforte, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
HIV Clinical Trials
|
November 14, 2018
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients
Chiara Dentone, Antonio Di Biagio, Alessandro Cozzi Lepri, et al.
Page
of 25
Search research articles
Search
Showing results (81-90 of 244) with videos related to
Sort By:
Page
of 25
The Journal of Antimicrobial Chemotherapy
|
June 8, 2019
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL
Nicola Gianotti, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
AIDS (London, England)
|
April 13, 2004
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy
Michela Violin, Alessandro Cozzi-Lepri, Rossella Velleca, et al.
AIDS (London, England)
|
April 7, 2007
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
Alessandro Cozzi-Lepri, Andrew N Phillips, Lidia Ruiz, et al.
Antiviral Therapy
|
April 14, 2010
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy
Antonella Castagna, Laura Galli, Carlo Torti, et al.
The Journal of Infectious Diseases
|
July 17, 2009
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings
Alessandro Cozzi-Lepri, Andrew N Phillips, Javier Martinez-Picado, et al.
The Journal of Antimicrobial Chemotherapy
|
September 11, 2019
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort
Lucia Taramasso, Patrizia Lorenzini, Antonio Di Biagio, et al.
HIV Medicine
|
April 28, 2025
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort
Andrea De Vito, Alessandro Tavelli, Alessandro Cozzi-Lepri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 13, 2005
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study
Rita Murri, Alessandro Cozzi Lepri, Paola Cicconi, et al.
HIV Clinical Trials
|
March 2, 2018
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort<sup/>
Antonella d'Arminio Monforte, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
HIV Clinical Trials
|
November 14, 2018
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients
Chiara Dentone, Antonio Di Biagio, Alessandro Cozzi Lepri, et al.
Page
of 25